Capital Analysts LLC’s VanEck Biotech ETF BBH Stock Holding History

Capital Analysts LLC’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-406	Closed	-$65K	–	975
2022 Q4	$65K	Buy	406 +2	+0.5%	+$317	﹤0.01%	573
2022 Q3	$57K	Hold	404	–	–	﹤0.01%	542
2022 Q2	$59K	Hold	404	–	–	﹤0.01%	525
2022 Q1	$66K	Hold	404	–	–	﹤0.01%	508
2021 Q4	$77K	Buy	404 +1	+0.2%	+$193	﹤0.01%	500
2021 Q3	$82K	Hold	403	–	–	0.01%	491
2021 Q2	$81K	Hold	403	–	–	0.01%	488
2021 Q1	$71K	Buy	+403	New	+$72.9K	﹤0.01%	529

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Analysts LLC's BBH Position: Q1 2023 in Review

Capital Analysts LLC sold out of VanEck Biotech ETF (BBH) in Q1 2023, closing a stake of 406 shares — an estimated $65K sold.

Capital Analysts LLC first reported a position in BBH in Q1 2021 and held it in 8 quarters. The position peaked at $82K in Q3 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2023.

Capital Analysts LLC reported no remaining VanEck Biotech ETF position as of Q1 2023 after selling out during the quarter.
Capital Analysts LLC sold 406 VanEck Biotech ETF shares in Q1 2023, an estimated $65K.
Capital Analysts LLC first reported a position in VanEck Biotech ETF in Q1 2021 and held it in 8 quarters.
Capital Analysts LLC's VanEck Biotech ETF position peaked at $82K in Q3 2021.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2023.

Based on Capital Analysts LLC's 13F filing for Q1 2023, filed 5 May 2023.